Print

Purpose

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria. - Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA) therapy], and at least 3 prior lines of therapy (LOT). - Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria. - Participants must have measurable disease during screening. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria

  • Active or history of central nervous system involvement with MM. - Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. - Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis. - Other protocol-defined Inclusion/Exclusion criteria apply.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
BMS-986393
  • Biological: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266,
    • GPRC5D CAR T cells

Recruiting Locations

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Sharmilan Thanendrarajan, Site 0037
501-526-6000

UCLA Hematology/Oncology - Westwood (Building 200 Suite 214)
Los Angeles, California 90095
Contact:
Sarah Larson, Site 0028
310-829-5471

UCSF Helen Diller Medical Center at Parnassus Heights
San Francisco, California 94143
Contact:
Anupama Kumar, Site 0018
415-514-0768

Colorado Blood Cancer Institute
Denver, Colorado 80218
Contact:
Tara Gregory, Site 0049
720-754-4800

Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida 33176
Contact:
George Nahas, Site 0045
201-310-8558

Moffitt Cancer Center
Tampa, Florida 33612
Contact:
Ciara Freeman, Site 0029
813-745-2475

Winship Cancer Institute of Emory University
Atlanta, Georgia 30322
Contact:
Nisha Joseph, Site 0009
502-608-5503

Northside Hospital
Atlanta, Georgia 30342
Contact:
Scott Solomon, Site 0004
404-255-1930

Northwestern Memorial Hospital
Chicago, Illinois 60611
Contact:
Seema Singhal, Site 0005
312-505-1290

University of Iowa
Iowa City, Iowa 52242
Contact:
Chris Strouse, Site 0019
630-917-8956

The University of Kansas Cancer Center - Westwood
Westwood, Kansas 66205
Contact:
Leyla Shune, Site 0016
913-588-6029

Norton Women's and Children's Hospital
Saint Matthews, Kentucky 40207
Contact:
Don Stevens, Site 0026
502-899-3366

Massachusetts General Hospital
Boston, Massachusetts 02114
Contact:
Diana Cirstea, Site 0039
617-724-4000

Dana-Farber Cancer Institute
Boston, Massachusetts 02215
Contact:
Omar Nadeem, Site 0036
617-632-3000

Washington University School of Medicine
Saint Louis, Missouri 63110
Contact:
Michael Slade, Site 0010
314-454-8304

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey 08901
Contact:
Mansi Shah, Site 0034
732-209-5479

Roswell Park Cancer Institute
Buffalo, New York 14263
Contact:
Ehsan Malek, Site 0046
716-845-8722

Icahn School of Medicine at Mount Sinai
New York, New York 10029
Contact:
Adriana Rossi, Site 0002
646-962-6500

University of North Carolina Medical Center
Chapel Hill, North Carolina 27599
Contact:
Eben Lichtman, Site 0031
617-842-6051

Oncology Hematology Care
Cincinnati, Ohio 45242
Contact:
James Essell, Site 0054
513-686-5482

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
Contact:
Srinivas Devarakonda, Site 0032
570-423-0522

Oregon Health and Science University
Portland, Oregon 97239
Contact:
Amrita Desai, Site 0038
503-494-0896

University of Texas MD Anderson Cancer Center
Houston, Texas 77030
Contact:
Krina Patel, Site 0027
713-792-6662

Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute
San Antonio, Texas 78229
Contact:
Paul Shaughnessy, Site 0055
210-575-6904

LDS Hospital
Salt Lake City, Utah 84143
Contact:
Bradley Hunter, Site 0050
801-419-6498

Fred Hutchinson Cancer Center
Seattle, Washington 98109
Contact:
Rahul Banerjee, Site 0011

University Hospital and UW Health Clinics
Madison, Wisconsin 53792
Contact:
Zhubin Gahvari, Site 0015
608-262-9317

More Details

NCT ID
NCT06297226
Status
Recruiting
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.